West Pharmaceutical Services Inc. (NYSE:WST) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado lessened its stake in West Pharmaceutical Services Inc. (NYSE:WST) by 3.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 146,853 shares of the medical instruments supplier’s stock after selling 4,808 shares during the period. Public Employees Retirement Association of Colorado owned about 0.20% of West Pharmaceutical Services worth $18,379,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Advisor Group Inc. lifted its position in shares of West Pharmaceutical Services by 7.8% during the 2nd quarter. Advisor Group Inc. now owns 18,033 shares of the medical instruments supplier’s stock worth $2,257,000 after purchasing an additional 1,299 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of West Pharmaceutical Services by 1.6% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 13,720 shares of the medical instruments supplier’s stock worth $1,717,000 after purchasing an additional 220 shares during the last quarter. Aperio Group LLC lifted its position in shares of West Pharmaceutical Services by 2.2% during the 2nd quarter. Aperio Group LLC now owns 44,876 shares of the medical instruments supplier’s stock worth $5,616,000 after purchasing an additional 955 shares during the last quarter. Dupont Capital Management Corp lifted its position in shares of West Pharmaceutical Services by 47.5% during the 2nd quarter. Dupont Capital Management Corp now owns 11,731 shares of the medical instruments supplier’s stock worth $1,468,000 after purchasing an additional 3,776 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of West Pharmaceutical Services by 4.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,454 shares of the medical instruments supplier’s stock worth $557,000 after purchasing an additional 187 shares during the last quarter. Hedge funds and other institutional investors own 91.76% of the company’s stock.

Several research firms have recently issued reports on WST. Jefferies Financial Group cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price objective for the company. in a research report on Wednesday, May 1st. William Blair began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, April 23rd. They set an “outperform” rating and a $112.16 price objective for the company. Bank of America raised shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research report on Friday, July 26th. Finally, Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research report on Saturday, August 3rd. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $130.72.

WST traded down $2.67 on Wednesday, reaching $142.40. The company had a trading volume of 2,898 shares, compared to its average volume of 375,605. West Pharmaceutical Services Inc. has a 1 year low of $91.75 and a 1 year high of $145.14. The company has a market cap of $10.70 billion, a PE ratio of 50.83, a PEG ratio of 4.10 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.02 and a quick ratio of 2.27. The stock’s 50-day simple moving average is $129.52.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.17. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The firm had revenue of $469.70 million during the quarter, compared to analysts’ expectations of $459.90 million. During the same period in the previous year, the company earned $0.70 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities analysts expect that West Pharmaceutical Services Inc. will post 3.07 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be given a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, October 22nd. This represents a $0.60 dividend on an annualized basis and a yield of 0.42%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: How is a price target determined?

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply